Scott M. Knowles

1.3k total citations
24 papers, 880 citations indexed

About

Scott M. Knowles is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Scott M. Knowles has authored 24 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Scott M. Knowles's work include Radiopharmaceutical Chemistry and Applications (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Scott M. Knowles is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Scott M. Knowles collaborates with scholars based in United States, France and United Kingdom. Scott M. Knowles's co-authors include Anna M. Wu, Kirstin A. Zettlitz, Felix B. Salazar, Richard Tavaré, Tove Olafsen, Robert E. Reiter, David B. Stout, Owen N. Witte, Melissa McCracken and Xiaohong Li and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Scott M. Knowles

23 papers receiving 864 citations

Peers

Scott M. Knowles
Masahide Matsuda Japan
Shahar Frenkel Israel
Ryuhei Kitai Japan
Ulf Nestler Germany
John T. Kemshead United Kingdom
Robert Cavaliere United States
Almuth F. Keßler Germany
Yan Ma United States
Vikas Khetan India
Toshio Sasajima Japan
Masahide Matsuda Japan
Scott M. Knowles
Citations per year, relative to Scott M. Knowles Scott M. Knowles (= 1×) peers Masahide Matsuda

Countries citing papers authored by Scott M. Knowles

Since Specialization
Citations

This map shows the geographic impact of Scott M. Knowles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott M. Knowles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott M. Knowles more than expected).

Fields of papers citing papers by Scott M. Knowles

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott M. Knowles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott M. Knowles. The network helps show where Scott M. Knowles may publish in the future.

Co-authorship network of co-authors of Scott M. Knowles

This figure shows the co-authorship network connecting the top 25 collaborators of Scott M. Knowles. A scholar is included among the top collaborators of Scott M. Knowles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott M. Knowles. Scott M. Knowles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521. 3 indexed citations
2.
Raychaudhuri, Suravi, Zhao Dong, Scott M. Knowles, & Solomon A. Graf. (2024). EBV‐Positive Classic Hodgkin Lymphoma and Primary Nodal T‐Cell/NK‐Cell Lymphoma Arising in the Background of Follicular Lymphoma. SHILAP Revista de lepidopterología. 2024(1). 8810646–8810646.
3.
4.
Heiser, Ryan A., Michelle Ulrich, Jason D. Berndt, et al.. (2023). Abstract 3253: CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors. Cancer Research. 83(7_Supplement). 3253–3253. 3 indexed citations
5.
Iyer, Swaminathan P., Deepa Jagadeesh, Eva Domingo‐Doménech, et al.. (2023). P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032. HemaSphere. 7(S3). e4008899–e4008899. 2 indexed citations
6.
7.
Jagadeesh, Deepa, Scott M. Knowles, & Sarah McCue Horwitz. (2021). FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION (SGN35‐032, TRIAL IN PROGRESS). Hematological Oncology. 39(S2). 1 indexed citations
8.
Zettlitz, Kirstin A., Wen‐Ting K. Tsai, Scott M. Knowles, et al.. (2019). [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. Molecular Imaging and Biology. 22(2). 367–376. 10 indexed citations
9.
Zettlitz, Kirstin A., Wen‐Ting K. Tsai, Scott M. Knowles, et al.. (2018). Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti–Prostate Stem Cell Antigen Cys-Diabody. Journal of Nuclear Medicine. 59(9). 1398–1405. 39 indexed citations
10.
Zettlitz, Kirstin A., et al.. (2017). ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo. Clinical Cancer Research. 23(23). 7242–7252. 38 indexed citations
11.
Wong, Vincent Kam Wai, Kevin Y. Chen, Shijun Sung, et al.. (2016). Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)–Targeted Photothermal Therapy. SLAS TECHNOLOGY. 22(1). 26–35. 10 indexed citations
12.
Sonn, Geoffrey A., Ziyue Karen Jiang, Kirstin A. Zettlitz, et al.. (2015). Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clinical Cancer Research. 22(6). 1403–1412. 41 indexed citations
13.
Knowles, Scott M., Richard Tavaré, Kirstin A. Zettlitz, et al.. (2014). Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. Clinical Cancer Research. 20(24). 6367–6378. 25 indexed citations
14.
Wilks, Moses Q., Scott M. Knowles, Anna M. Wu, & Sung‐Cheng Huang. (2014). Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging. Journal of Nuclear Medicine. 55(9). 1539–1544. 11 indexed citations
15.
Knowles, Scott M., Kirstin A. Zettlitz, Richard Tavaré, et al.. (2014). Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody. Journal of Nuclear Medicine. 55(3). 452–459. 50 indexed citations
16.
Rochefort, Matthew M., Mark D. Girgis, Scott M. Knowles, et al.. (2014). A Mutated Anti-CA19-9 scFv-Fc for Positron Emission Tomography of Human Pancreatic Cancer Xenografts. Molecular Imaging and Biology. 16(5). 721–729. 12 indexed citations
17.
Tavaré, Richard, Melissa McCracken, Kirstin A. Zettlitz, et al.. (2014). Engineered antibody fragments for immuno-PET imaging of endogenous CD8 + T cells in vivo. Proceedings of the National Academy of Sciences. 111(3). 1108–1113. 131 indexed citations
18.
Rodriguez, April R., et al.. (2013). Endocytosis and Intracellular Trafficking Properties of Transferrin-Conjugated Block Copolypeptide Vesicles. Biomacromolecules. 14(5). 1458–1464. 23 indexed citations
19.
Kenanova, Vania, Tove Olafsen, Felix B. Salazar, et al.. (2010). Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Engineering Design and Selection. 23(10). 789–798. 28 indexed citations
20.
Yang, Feng‐Chun, David A. Ingram, Shi Chen, et al.. (2008). Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow. Cell. 135(3). 437–448. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahide Matsuda Breakdown of academic impact, for papers by Shahar Frenkel Breakdown of academic impact, for papers by Ryuhei Kitai Breakdown of academic impact, for papers by Ulf Nestler Breakdown of academic impact, for papers by John T. Kemshead Breakdown of academic impact, for papers by Robert Cavaliere Breakdown of academic impact, for papers by Almuth F. Keßler Breakdown of academic impact, for papers by Yan Ma Breakdown of academic impact, for papers by Vikas Khetan Breakdown of academic impact, for papers by Toshio Sasajima
Rankless by CCL
2026